Strategies for managing risk in equity
Founders, senior executives, and venture capitalists often own restricted equity in startup companies, which they must manage proactively to minimize the risk and maximize value, says C. Mark Tang.
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2002-06, Vol.20 (Suppl 6), p.BE57-BE60 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | BE60 |
|---|---|
| container_issue | Suppl 6 |
| container_start_page | BE57 |
| container_title | Nature biotechnology |
| container_volume | 20 |
| creator | Tang, C. Mark |
| description | Founders, senior executives, and venture capitalists often own restricted equity in startup companies, which they must manage proactively to minimize the risk and maximize value, says C. Mark Tang. |
| doi_str_mv | 10.1038/nbt0602supp-BE57 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_71865302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A190114542</galeid><sourcerecordid>A190114542</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4187-d38c1e8af8a136f5be1c6e36eb5d65612e1db65737cf629a410eeb6a7c5736a13</originalsourceid><addsrcrecordid>eNqNkUtLxDAUhYMoPkb3rqS4EFxUc9vmtl2q-AJhwNc2pOltiU7TMWlB_70ZZsAHCCaLhJvvnOTmMLYP_AR4WpzaauDIEz_O5_H5pcjX2DaIDGPAEtfDnhd5zEHgFtvx_oVzjhniJtuChBelKGGbHT0MTg3UGvJR07uoU1a1xraRM_41Mjait9EMH7tso1EzT3urdcKeri4fL27iu-n17cXZXawzCHfVaaGBCtUUClJsREWgkVKkStQoEBKCukKRp7luMClVBpyoQpXrUMOgmbCjpe_c9W8j-UF2xmuazZSlfvQyhwJFypMAHv4CX_rR2fA2mYSRB7ssQCdLqFUzksY2fWhWh1lTZ3RvqTGhfgYlB8hEtnA9_iEIzEDvQ6tG7-Xtw_3_2enzT5YvWe167x01cu5Mp9yHBC4XScpvScpFkkFysGpwrDqqvwSr6AIAS8CHI9uS-_qBP00_ATO3p-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222277364</pqid></control><display><type>article</type><title>Strategies for managing risk in equity</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Tang, C. Mark</creator><creatorcontrib>Tang, C. Mark</creatorcontrib><description>Founders, senior executives, and venture capitalists often own restricted equity in startup companies, which they must manage proactively to minimize the risk and maximize value, says C. Mark Tang.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/nbt0602supp-BE57</identifier><identifier>PMID: 12089591</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Agriculture ; Bioinformatics ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biotechnology ; Biotechnology - economics ; Commerce - economics ; Entrepreneurship - economics ; Investments ; legal-and-finance ; Life Sciences ; Ownership ; Risk Management - economics ; United States</subject><ispartof>Nature biotechnology, 2002-06, Vol.20 (Suppl 6), p.BE57-BE60</ispartof><rights>Springer Nature America, Inc. 2002</rights><rights>COPYRIGHT 2002 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nbt0602supp-BE57$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nbt0602supp-BE57$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12089591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, C. Mark</creatorcontrib><title>Strategies for managing risk in equity</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>Founders, senior executives, and venture capitalists often own restricted equity in startup companies, which they must manage proactively to minimize the risk and maximize value, says C. Mark Tang.</description><subject>Agriculture</subject><subject>Bioinformatics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Biotechnology - economics</subject><subject>Commerce - economics</subject><subject>Entrepreneurship - economics</subject><subject>Investments</subject><subject>legal-and-finance</subject><subject>Life Sciences</subject><subject>Ownership</subject><subject>Risk Management - economics</subject><subject>United States</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkUtLxDAUhYMoPkb3rqS4EFxUc9vmtl2q-AJhwNc2pOltiU7TMWlB_70ZZsAHCCaLhJvvnOTmMLYP_AR4WpzaauDIEz_O5_H5pcjX2DaIDGPAEtfDnhd5zEHgFtvx_oVzjhniJtuChBelKGGbHT0MTg3UGvJR07uoU1a1xraRM_41Mjait9EMH7tso1EzT3urdcKeri4fL27iu-n17cXZXawzCHfVaaGBCtUUClJsREWgkVKkStQoEBKCukKRp7luMClVBpyoQpXrUMOgmbCjpe_c9W8j-UF2xmuazZSlfvQyhwJFypMAHv4CX_rR2fA2mYSRB7ssQCdLqFUzksY2fWhWh1lTZ3RvqTGhfgYlB8hEtnA9_iEIzEDvQ6tG7-Xtw_3_2enzT5YvWe167x01cu5Mp9yHBC4XScpvScpFkkFysGpwrDqqvwSr6AIAS8CHI9uS-_qBP00_ATO3p-U</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>Tang, C. Mark</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Strategies for managing risk in equity</title><author>Tang, C. Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4187-d38c1e8af8a136f5be1c6e36eb5d65612e1db65737cf629a410eeb6a7c5736a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Agriculture</topic><topic>Bioinformatics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Biotechnology - economics</topic><topic>Commerce - economics</topic><topic>Entrepreneurship - economics</topic><topic>Investments</topic><topic>legal-and-finance</topic><topic>Life Sciences</topic><topic>Ownership</topic><topic>Risk Management - economics</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, C. Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, C. Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies for managing risk in equity</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>20</volume><issue>Suppl 6</issue><spage>BE57</spage><epage>BE60</epage><pages>BE57-BE60</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>Founders, senior executives, and venture capitalists often own restricted equity in startup companies, which they must manage proactively to minimize the risk and maximize value, says C. Mark Tang.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>12089591</pmid><doi>10.1038/nbt0602supp-BE57</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2002-06, Vol.20 (Suppl 6), p.BE57-BE60 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71865302 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online |
| subjects | Agriculture Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Biotechnology - economics Commerce - economics Entrepreneurship - economics Investments legal-and-finance Life Sciences Ownership Risk Management - economics United States |
| title | Strategies for managing risk in equity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A31%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20for%20managing%20risk%20in%20equity&rft.jtitle=Nature%20biotechnology&rft.au=Tang,%20C.%20Mark&rft.date=2002-06-01&rft.volume=20&rft.issue=Suppl%206&rft.spage=BE57&rft.epage=BE60&rft.pages=BE57-BE60&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/nbt0602supp-BE57&rft_dat=%3Cgale_proqu%3EA190114542%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222277364&rft_id=info:pmid/12089591&rft_galeid=A190114542&rfr_iscdi=true |